Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SE 203580

被引:99
作者
Eyers, PA
van den Ijssel, P
Quinlan, RA
Goedert, M
Cohen, P
机构
[1] Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland
[2] Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland
[3] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
基金
英国惠康基金;
关键词
SAPK2; p38; SB203580; MAPKAP-K2; MSK1; CREB;
D O I
10.1016/S0014-5793(99)00552-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Stress-activated protein kinase 2a, also called p38, is inhibited by SE 203580 and this drug has been used widely to implicate this enzyme in the regulation of many physiological processes. Here, me introduce a novel method of general application, which can be used to establish whether the effects of SE 203580 are mediated via inhibition of stress-activated protein kinase 2a/p38 or whether they result from 'non-specific' effects. Four events thought to occur upon activation of stress-activated protein kinase 2a/p38 have been established unequivocally. These are the activation of mitogen-activated protein kinase-activated protein kinase-2 and mitogen- and stress-activated protein kinase-1 and the phosphorylation of their presumed substrates, heat shock protein 27 and the transcription factor cyclic AMP response element binding protein, respectively. In contrast, the SB 203580-induced activation of c-Raf is independent of stress-activated protein kinase 2a/p38 inhibition. (C) 1999 Federation of European Biochemical Societies.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 25 条
  • [1] ALESSI DR, 1995, METHOD ENZYMOL, V255, P279
  • [2] BADGER AM, 1996, J PHARMACOL EXP THER, V279, P1458
  • [3] The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor
    Beyaert, R
    Cuenda, A
    VandenBerghe, W
    Plaisance, S
    Lee, JC
    Haegeman, G
    Cohen, P
    Fiers, W
    [J]. EMBO JOURNAL, 1996, 15 (08) : 1914 - 1923
  • [4] Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059 -: SB 203580 also inhibits thromboxane synthase
    Börsch-Haubold, AG
    Pasquet, S
    Watson, SP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) : 28766 - 28772
  • [6] COHEN P, 1999, IN PRESS CURR OPIN C
  • [7] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    [J]. FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [8] Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB
    Deak, M
    Clifton, AD
    Lucocq, JM
    Alessi, DR
    [J]. EMBO JOURNAL, 1998, 17 (15) : 4426 - 4441
  • [9] Conversion of SB 203580-insensitive MBP kinase family members to drug-sensitive forms by a single amino-acid substitution
    Eyers, PA
    Craxton, M
    Morrice, N
    Cohen, P
    Goedert, M
    [J]. CHEMISTRY & BIOLOGY, 1998, 5 (06): : 321 - 328
  • [10] A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase
    Fox, T
    Coll, JT
    Xie, XL
    Ford, PJ
    Germann, UA
    Porter, MD
    Pazhanisamy, S
    Fleming, MA
    Galullo, V
    Su, MSS
    Wilson, KP
    [J]. PROTEIN SCIENCE, 1998, 7 (11) : 2249 - 2255